Compare AVO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVO | GERN |
|---|---|---|
| Founded | 1983 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.7M | 753.3M |
| IPO Year | 2020 | 1996 |
| Metric | AVO | GERN |
|---|---|---|
| Price | $12.71 | $1.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $17.00 | $3.00 |
| AVG Volume (30 Days) | 267.5K | ★ 6.9M |
| Earning Date | 12-18-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.53 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $1,426,600,000.00 | $183,403,000.00 |
| Revenue This Year | $11.93 | $147.34 |
| Revenue Next Year | N/A | $39.11 |
| P/E Ratio | $23.00 | ★ N/A |
| Revenue Growth | 25.34 | ★ 522.13 |
| 52 Week Low | $9.56 | $1.04 |
| 52 Week High | $15.25 | $4.01 |
| Indicator | AVO | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 67.25 | 60.64 |
| Support Level | $11.88 | $1.21 |
| Resistance Level | $12.15 | $1.42 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 93.87 | 74.14 |
Mission Produce Inc is engaged in the business of producing and distributing avocados, serving retail, wholesale, and food service customers. Also, the company provides additional services like ripening, bagging, custom packing, and logistical management. The company's operating segments include Marketing and Distribution, International Farming and Blueberries. It generates maximum revenue from the Marketing and Distribution segment. The Marketing and Distribution segment sources fruit mainly from growers and then distributes fruit through a distribution network. Geographically distributed across North America, China, Europe, and the U.K.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.